GSA Capital Partners LLP Takes $739,000 Position in Janux Therapeutics, Inc. $JANX

GSA Capital Partners LLP purchased a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 48,139 shares of the company’s stock, valued at approximately $739,000.

Several other large investors have also recently added to or reduced their stakes in JANX. Versant Capital Management Inc lifted its position in Janux Therapeutics by 42.8% in the second quarter. Versant Capital Management Inc now owns 2,615 shares of the company’s stock valued at $40,000 after purchasing an additional 784 shares during the period. Bank of America Corp DE boosted its holdings in Janux Therapeutics by 8.6% in the 1st quarter. Bank of America Corp DE now owns 801,646 shares of the company’s stock valued at $11,143,000 after purchasing an additional 63,316 shares in the last quarter. Irenic Capital Management LP acquired a new position in Janux Therapeutics during the 1st quarter worth approximately $10,645,000. ADAR1 Capital Management LLC increased its position in Janux Therapeutics by 21.6% during the 1st quarter. ADAR1 Capital Management LLC now owns 298,546 shares of the company’s stock worth $4,150,000 after purchasing an additional 53,094 shares during the period. Finally, Rock Springs Capital Management LP raised its stake in shares of Janux Therapeutics by 2.3% during the 1st quarter. Rock Springs Capital Management LP now owns 367,009 shares of the company’s stock worth $5,101,000 after buying an additional 8,211 shares in the last quarter. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Trading Up 3.3%

Shares of Janux Therapeutics stock opened at $17.52 on Thursday. Janux Therapeutics, Inc. has a 12-month low of $12.12 and a 12-month high of $35.34. The stock has a market cap of $1.07 billion, a PE ratio of -10.68 and a beta of 2.50. The company has a 50-day moving average of $15.51 and a two-hundred day moving average of $14.58.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.10). The firm had revenue of $10.27 million for the quarter, compared to the consensus estimate of $19.07 million. On average, sell-side analysts forecast that Janux Therapeutics, Inc. will post -1.76 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on JANX. Stifel Nicolaus set a $35.00 price target on Janux Therapeutics in a report on Friday, August 7th. Piper Sandler dropped their price objective on Janux Therapeutics from $30.00 to $26.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. JonesTrading cut their price objective on Janux Therapeutics from $50.00 to $28.00 and set a “buy” rating for the company in a research report on Tuesday, April 28th. Guggenheim cut their price objective on Janux Therapeutics from $58.00 to $55.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Finally, Truist Financial reissued a “buy” rating and issued a $26.00 target price (down from $80.00) on shares of Janux Therapeutics in a report on Thursday, June 25th. Nine analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $37.58.

Insiders Place Their Bets

In related news, insider Janeen Noel Doyle sold 4,059 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $14.03, for a total value of $56,947.77. Following the completion of the transaction, the insider directly owned 75,941 shares of the company’s stock, valued at $1,065,452.23. This trade represents a 5.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 7.90% of the stock is owned by insiders.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.